OVERVIEW

Clinical Advances in the Diagnosis and Management of Pulmonary Hypertension is organized by Scripps Conference Services CME.

Released On: April 7, 2021
Expires On: October 7, 2021

Target Audience:
This activity is intended for physicians and other health care practitioners treating patients with various types of pulmonary hypertension.

CME Accreditation:
Physicians:
Scripps Health designates this internet enduring material for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants:
PAs may claim a maximum of 4 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Program Overview:
This continuing education activity covers all forms of pulmonary hypertension. Expert faculty discuss the epidemiology of PH, how PH is diagnosed, and the poor outcomes associated with PH when left untreated. Participants will be left with a better understanding of the difference between PAH and PVH and why the difference matters. Therapies for PAH and PVH will also be discussed with reference to current clinical guidelines.

Educational Objectives:
After completing this internet enduring material, participants should be able to:
• Describe the epidemiology and pathophysiology of pulmonary hypertension.
• Determine who is at risk for pulmonary hypertension and effectively diagnose patients.
• Recognize the difference between PAH and PVH and how this translates into therapy.
• Outline the current approach to pulmonary hypertension treatment in the presence of related or underlying diseases.
• Evaluate current pharmacologic and medical management strategies for patients with pulmonary hypertension.
• Incorporate novel therapies into patient care for improved outcomes.
• Identify when to refer patients for specialty treatment.